News

Mauna Kea Technologies Reports First Half 2025 Revenue 

28 July 2025

On Constant Currency Basis (CER), U.S. sales up +17% Y/Y in H1 and +23% in Q2 

Record U.S. sales productivity despite ongoing safeguard procedure 

Total revenue down 5% amid weaker EMEA and ROW sales results 

Further steps taken to improve Mauna Kea Technologies’ financial strength 

Paris and Boston, July 28, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced its revenue for the first half and the first two quarters of 2025, ended June 30, 2025. 

First Half of 2025 Performance Summary 

Total revenue for the first half of 2025 amounted to €3.7m, representing a slight decline of 5% compared to H1 2024. 

U.S. revenue for the first half of 2025 grew by +14% as reported and +17% in constant currency, with a significant dollar depreciation against the euro, especially in Q2 2025. U.S. operations remained robust, with accelerated growth in Q2 2025: sales rose +23% at constant currency vs. Q2 2024, and up +11% in Q1 2025 vs. Q1 2024, boosted by the expansion of the sales team. 

Growth in the U.S. was primarily driven by system and probe sales, particularly in the pancreatic cysts indication, more than offsetting a decline in PPU revenue due to the gradual impact of lower Medicare reimbursement rates starting in 2024. 

In Europe, business activity was gradually impacted by the Company’s financial context. However, this decline was almost entirely offset by strong performances in other regions. 

Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, stated: 

“This first half confirms the relevance of our strategic decisions in our primary market, the United States, where we are seeing continued and sustained sales growth. This momentum is all the more noteworthy given that it was achieved with a reduced sales force, reflecting a strong increase in sales productivity per representative, now at a record level of over $900K, compared to just $200K in 2021. 

We are also observing increased usage of Cellvizio and growing interest from new centers, particularly for indications such as pancreatic cysts and food intolerances. Pay-per-use procedure volumes have remained stable at over 800 per quarter for the past year, despite the reduction in Medicare reimbursement. The signing of three new hospitals at the end of H1 gives us confidence in a rebound in volumes going forward. 

In Europe and the rest of the world, where our approach remains more opportunistic due to the lack of reimbursement, our activity was impacted by the financial environment. We are currently restructuring the organization to quickly improve efficiency in the coming months, including geographic expansion into high-potential markets such as Australia, which we recently announced. 

The financial situation currently faced by Mauna Kea has, of course, had an impact on the Company’s operations. However, the slight decline in revenue for the first half reflects the resilience of our business model. During this period of focus on restructuring efforts, we view the revenue level achieved in H1 as a solid performance.” 

  • Update on Safeguard Procedure 

On July 10, 2025, Mauna Kea Technologies received court approval to initiate a “classes of affected parties” procedure, a framework introduced by the 2021 reform of France’s business insolvency law. This process groups creditors into different classes to vote on a comprehensive restructuring plan. 

In this framework, Mauna Kea Technologies will present a plan in the coming weeks, aimed at significantly reducing its debt, to be submitted to the vote by the various creditor classes. 

As a reminder, the Company’s current cash runway extends through November 2025. Discussions are underway, as part of this safeguard procedure, with strategic investors and family offices to secure long-term financing to support its sustainable development plan toward profitability. 

Key Highlights for the First Half 2025 

  • U.S. Commercial Productivity 

As of January 1st, 2025, the U.S. sales team had 4 representatives, down from 8 at the beginning of 2024. Despite this reduction, the revenue increased significantly over the half year period. 

Since mid-2024, new initiatives have been implemented, both in terms of sales tactics in response to Medicare reimbursement cuts and sales organization effectiveness, with the promotion of two representatives to national leadership roles. These actions have led to a significant increase in per-rep productivity, reaching historic levels of around $800K to $900K in annual sales per representative. 

This positive momentum also supported the hiring of two new sales representatives during the first half of 2025, who quickly became operational. 

  • Pay-Per-Use (PPU) Procedure Volumes 

PPU procedure volume, which had gradually slowed in 2024 due to Medicare reimbursement cuts, has stabilized at over 800 procedures per quarter. 

At the end of Q2 2025, three new PPU accounts were signed, marking the first new contracts since Q3 2024. This recovery signals renewed commercial momentum and indicates potential for volume rebound. 

Furthermore, the Company is actively working toward a reimbursement reclassification, notably by correcting hospital-submitted reporting data and collaborating closely with physician associations and Medicare authorities. 


Revenue by Geography – H1 2025 

By geography, business was mainly driven by the U.S., where the Company recorded a +14% growth as reported and +17% at constant currency (CC), with a dollar depreciation against the euro, especially in Q2 2025. This growth was primarily driven by system and probe sales, particularly in the pancreatic cysts indication, offsetting a decline in PPU revenue due to the gradual impact of lower Medicare reimbursement rates starting in 2024. 

In Europe, business activity was gradually impacted by the Company’s financial context. However, this decline was almost entirely offset by strong performances in other regions. 


“We remain fully committed to ensuring that the safeguard procedure results in a situation that allows Mauna Kea Technologies to achieve financial stability. At the same time, we are actively structuring the financial resources necessary to execute our development plan, with the aim of transforming Mauna Kea into a Company that delivers both growth and profitability”, concluded Sacha Loiseau

READ THE COMPLETE PRESS RELEASE

Latest News

Mauna Kea Technologies Enters Australian Market with Endotherapeutics Partnership 

Mauna Kea Technologies Enters Australian Market with Endotherapeutics Partnership 

Mauna Kea Technologies Strengthens its Leading Role in the AI-based Endomicroscopic Imaging Ecosystem with its 14th Patent Granted in the U.S. 

Mauna Kea Technologies Strengthens its Leading Role in the AI-based Endomicroscopic Imaging Ecosystem with its 14th Patent Granted in the U.S. 

Mauna Kea Technologies Congratulates Stanford Health Care on Completing 100 Food Intolerance Cases with Cellvizio 

Mauna Kea Technologies Congratulates Stanford Health Care on Completing 100 Food Intolerance Cases with Cellvizio 

No results found.